Enoblituzumab MGA271|cas:1353485-38-7|西域试剂

Enoblituzumab MGA271,97.71%

产品编号：Bellancom-P9966| CAS NO：1353485-38-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P9966	￥3500.00	杭州北京（现货）
Bellancom-P9966	￥9100.00	杭州北京（现货）
Bellancom-P9966	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Enoblituzumab MGA271

产品介绍

Enoblituzumab 是一种人源化 IgG1κ 单克隆抗体，可以识别人 B7-H3 蛋白 (B7 家族的免疫调节剂成员)。

生物活性

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.

体外研究

Enoblituzumab interacts with B7-H3 and causes strong antibody-dependent cellular cytotoxicity (ADCC) against a wide spectrum of cancer cells.
Enoblituzumab (0.01 ng/mL-10 mg/mL) mediates antibody-dependent cellular cytotoxicity (ADCC) against A498 cells with cynomolgus monkey peripheral blood mononuclear cells (PBMCs).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a C_max of 43 mg/mL in mice (mCD16^-/^-hCD16A⁺) that murine CD16 gene knocked out and are transgenic for human CD16A-158F.
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mCD16^-/^-hCD16A⁺ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)
Dosage:	1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:	Intravenous injection; once weekly; 5 weeks
Result:	Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment. Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mCD16^-/^-hCD16A⁺ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)
Dosage:	1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:	Intravenous injection; once weekly; 5 weeks
Result:	Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment. Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.